Latest News
Search News
Research reveals how breast cancer drug can accelerate cancer cell growth
1st May 2018
The breast cancer drug lapatinib which is designed to shrink tumours can sometimes cause them to grow in the lab, according to a new study published in eLife. By understanding the molecular basis of this phenomenon, scientists hope that their findings will lead to safer treatment options and drug design in the future.
Read more
Using a modified adenovirus to overcome treatment resistance in prostate cancer
27th April 2018
Researchers from BCI’s Centre for Molecular Oncology, led by Dr Gunnel Halldén, have identified a mechanism by which a modified flu-like virus, called AdDD, is able to negate resistance to a drug called mitoxantrone and increase tumour cell killing in prostate cancer models. This mechanism is dependent on B-cell lymphoma 2 (Bcl-2)- a protein involved in the regulation of cell death (apoptosis).
Read more
BCI and KCL collaboration develops a clinically-relevant CAR T cell imaging system
19th April 2018
A collaboration involving researchers from BCI’s Centre for Molecular Oncology, led by Dr Jane Sosabowski, and the ImmunoEngineering Group of King’s College London (KCL), led by Dr Sophie Papa, has developed an effective and clinically-relevant imaging system to monitor chimeric antigen receptor (CAR) T cells within the body. This system reduced the tumour burden in a pre-clinical model of prostate cancer and allowed for repeated and non-invasive assessment of CAR T cell localisation.
Read more
UK charities join forces to fund the work of Dr Angus Cameron
5th April 2018
BCI’s Dr Angus Cameron, Centre for Tumour Biology, is to receive joint funding from Worldwide Cancer Research and Pancreatic Cancer Research Fund (PCRF) to support vital research on pancreatic cancer. The charities have awarded equal sums totalling £235,000 to support the work of Dr Cameron and his laboratory group.
Read more
Determining the mechanisms of response and resistance to treatment in bladder cancer
29th March 2018
A worldwide collaboration involving BCI’s Prof Thomas Powles, Centre for Experimental Cancer Medicine, has revealed mechanisms involved in the development of response and resistance to an immune checkpoint inhibitor in metastatic urothelial cancer. The findings may highlight ways to improve the efficacy of this treatment in the hope of achieving long-term remission for patients.
Read more
Follicular lymphoma marked by spatial tumour heterogeneity
23rd March 2018
A research team at the BCI, Queen Mary University of London, led by Dr Jessica Okosun, Centre for Haemato-Oncology, has found that tumours at different sites within the same patient with follicular lymphoma can be genetically diverse. This suggests that a sole biopsy is incapable of capturing all the genetic events in any given individual and presents a significant challenge when providing targeted therapies to treat this disease.
Read more